Bicara 制药
BCAX
16.78
-0.84
-4.77%
Bicara 制药
US · BCAX
#3193 按市值排名
上市于 2024
16.78
-0.84
-4.77%
实时 - 追踪5344个代码 - 心跳于201秒前
· 2026-10-16 18:18
最新新闻
-
评级变动
Analysts Are Bullish on Top NA Stocks: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/12
-
评级变动
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $37\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)TipRanks · 2026/8/12
-
评级变动
BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $34\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
评级变动
BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $39\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
评级变动
Bicara Therapeutics Inc. (BCAX) Gets a Hold From Wells FargoTipRanks · 2026/6/2
-
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/13
-
评级变动
BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/6/2
-
评级变动
Analysts Offer Insights on NA Companies: Enhanced Group (ENHA), MNTN, Inc Class A (MNTN) and Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/12
-
评级变动
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/13
-
评级变动
Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/6/2
-
评级变动
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/6/2
-
BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35\u5e02\u573a\u8d44\u8baf · 2026/10/7
-
评级变动
Analysts Have Conflicting Sentiments on These NA Companies: Bending Spoons (BSP), EToro (ETOR) and Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/8/12
-
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Cuts Target Price to $45\u5e02\u573a\u8d44\u8baf · 2026/8/14
-
评级变动
BTIG Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $28\u5e02\u573a\u8d44\u8baf · 2026/7/28
-
评级变动
Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)TipRanks · 2026/5/27
-
评级变动
H.C. Wainwright Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $42\u5e02\u573a\u8d44\u8baf · 2026/6/1
-
评级变动
Analysts Offer Insights on NA Companies: Smithfield Foods (SFD), Bicara Therapeutics Inc. (BCAX) and Concentra Group Holdings Parent, Inc. (CON)TipRanks · 2026/8/12
-
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30\u5e02\u573a\u8d44\u8baf · 2026/9/8
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 18:18:37 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Bicara 制药 讨论区 0 条评论